Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: Results from a prospective study

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 69-76

  Roumeguère, Pauline ^a,b,d   Bouchard, Dominique ^a,c,d   Pigot, François ^c   Castinel, Alain ^c   Juguet, Frederic ^b,c,d   Gaye, Delphine ^a,d   Capdepont, Maylis ^b   Zerbib, Frank ^b   Laharie, David ^a,d  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c Talence   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Crohn's disease; infliximab; methotrexate; perineal fistula

Indexed keywords

INFLIXIMAB; METHOTREXATE;

ADULT; ALOPECIA; ANUS SPHINCTER; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CROHN DISEASE; COLON SURGERY; CYTOMEGALOVIRUS INFECTION; DEATH; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINEUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RECTOVAGINAL FISTULA; RECTUM FISTULA; RELAPSE; SIDE EFFECT;

EID: 78650147806     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21405     Document Type: Article

References (38)

1. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003; 125: 1508-1530.
2. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980; 21: 525-527. (Pubitemid 10059414)
3. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002; 122: 875-880.
4. Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007; 50: 1754-1760.
5. Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther. 2009; 30: 757-766.
6. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006; 55 (suppl 1): i36-i58.
7. Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrine glue injection for perianal fistulas in Crohn's disease: a randomized controlled trial. Gut. 2006; 55: A40.
8. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009; 15: 17-24.
9. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995; 123: 132-142.
10. Lecomte T, Contou JF, Beaugerie L, et al. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum. 2003; 46: 1469-1475.
11. McKee RF, Keenan RA,. Perianal Crohn's disease-is it all bad news? Dis Colon Rectum. 1996; 39: 136-142.
12. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis. 2003; 35: 619-627.
13. Mahadevan U, Marion JF, Present DH,. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther. 2003; 18: 1003-1008.
14. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 1398-1405. (Pubitemid 29205403)
15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
16. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003; 98: 332-339.
17. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58: 940-948.
18. Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum. 2003; 46: 577-583.
19. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004; 19: 295-301.
20. Laharie D, Zerbib F, Adhoute X, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther. 2006; 23: 1621-1628.
21. Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003; 17: 387-393.
22. Tougeron D, Savoye G, Savoye-Collet C, et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci. 2009; 54: 1746-1752.
23. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009; 104: 2973-2986.
24. van der Hagen SJ, Baeten CG, Soeters PB, et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum. 2005; 48: 758-767.
25. Takesue Y, Ohge H, Yokoyama T, et al. Long-term results of seton drainage on complex anal fistulae in patients with Crohn's disease. J Gastroenterol. 2002; 37: 912-915.
26. Thornton M, Solomon MJ,. Long-term indwelling seton for complex anal fistulas in Crohn's disease. Dis Colon Rectum. 2005; 48: 459-463.
27. Makowiec F, Jehle EC, Becker HD, et al. Perianal abscess in Crohn's disease. Dis Colon Rectum. 1997; 40: 443-450.
28. Hyder SA, Travis SP, Jewell DP, et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006; 49: 1837-1841.
29. Regueiro M, Mardini H,. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003; 9: 98-103.
30. Parsi MA, Lashner BA, Achkar JP, et al. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol. 2004; 99: 445-449.
31. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004; 2: 912-920.
32. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995; 332: 292-297.
33. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342: 1627-1632.
34. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000; 95: 1730-1734.
35. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226-1231.
36. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006; 130: 1054-1061.
37. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
38. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.